Frovatriptan versus almotriptan for acute treatment of menstrual migraine: Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study

Marco Bartolini, Maria Adelaide Giamberardino, Carlo Lisotto, Paolo Martelletti, Davide Moscato, Biagio Panascia, Lidia Savi, Luigi Alberto Pini, Grazia Sances, Patrizia Santoro, Giorgio Zanchin, Stefano Omboni, Michel D. Ferrari, Brigida Fierro, Filippo Brighina

Research output: Contribution to journalArticle

Abstract

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4 h was 36 and 53 % for frovatriptan and 41 and 50 % for almotriptan (p = NS between treatments). Rate of pain free at 2 and 4 h was 19 and 47 % with frovatriptan and 29 and 54 % for almotriptan (p = NS).At 24 h, 62 %of frovatriptan-treated and 67 %of almotriptan-treated patients had pain relief, while 60 versus 67 % were pain free (p = NS). Recurrence at 24 h was significantly (p

Original languageEnglish
Pages (from-to)401-406
Number of pages6
JournalJournal of Headache and Pain
Volume13
Issue number5
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Migraine Disorders
Therapeutics
Pain
Headache Disorders
Menstruation
Menstrual Cycle
Cross-Over Studies
almotriptan
frovatriptan
Safety
Recurrence
Population

Keywords

  • Almotriptan
  • Frovatriptan
  • Menstrually related migraine
  • Migraine

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Frovatriptan versus almotriptan for acute treatment of menstrual migraine : Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. / Bartolini, Marco; Giamberardino, Maria Adelaide; Lisotto, Carlo; Martelletti, Paolo; Moscato, Davide; Panascia, Biagio; Savi, Lidia; Pini, Luigi Alberto; Sances, Grazia; Santoro, Patrizia; Zanchin, Giorgio; Omboni, Stefano; Ferrari, Michel D.; Fierro, Brigida; Brighina, Filippo.

In: Journal of Headache and Pain, Vol. 13, No. 5, 07.2012, p. 401-406.

Research output: Contribution to journalArticle

Bartolini, M, Giamberardino, MA, Lisotto, C, Martelletti, P, Moscato, D, Panascia, B, Savi, L, Pini, LA, Sances, G, Santoro, P, Zanchin, G, Omboni, S, Ferrari, MD, Fierro, B & Brighina, F 2012, 'Frovatriptan versus almotriptan for acute treatment of menstrual migraine: Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study', Journal of Headache and Pain, vol. 13, no. 5, pp. 401-406. https://doi.org/10.1007/s10194-012-0455-4
Bartolini, Marco ; Giamberardino, Maria Adelaide ; Lisotto, Carlo ; Martelletti, Paolo ; Moscato, Davide ; Panascia, Biagio ; Savi, Lidia ; Pini, Luigi Alberto ; Sances, Grazia ; Santoro, Patrizia ; Zanchin, Giorgio ; Omboni, Stefano ; Ferrari, Michel D. ; Fierro, Brigida ; Brighina, Filippo. / Frovatriptan versus almotriptan for acute treatment of menstrual migraine : Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. In: Journal of Headache and Pain. 2012 ; Vol. 13, No. 5. pp. 401-406.
@article{4b3384e735734a52ba5aac28417f4e71,
title = "Frovatriptan versus almotriptan for acute treatment of menstrual migraine: Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study",
abstract = "The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4 h was 36 and 53 {\%} for frovatriptan and 41 and 50 {\%} for almotriptan (p = NS between treatments). Rate of pain free at 2 and 4 h was 19 and 47 {\%} with frovatriptan and 29 and 54 {\%} for almotriptan (p = NS).At 24 h, 62 {\%}of frovatriptan-treated and 67 {\%}of almotriptan-treated patients had pain relief, while 60 versus 67 {\%} were pain free (p = NS). Recurrence at 24 h was significantly (p",
keywords = "Almotriptan, Frovatriptan, Menstrually related migraine, Migraine",
author = "Marco Bartolini and Giamberardino, {Maria Adelaide} and Carlo Lisotto and Paolo Martelletti and Davide Moscato and Biagio Panascia and Lidia Savi and Pini, {Luigi Alberto} and Grazia Sances and Patrizia Santoro and Giorgio Zanchin and Stefano Omboni and Ferrari, {Michel D.} and Brigida Fierro and Filippo Brighina",
year = "2012",
month = "7",
doi = "10.1007/s10194-012-0455-4",
language = "English",
volume = "13",
pages = "401--406",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "5",

}

TY - JOUR

T1 - Frovatriptan versus almotriptan for acute treatment of menstrual migraine

T2 - Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study

AU - Bartolini, Marco

AU - Giamberardino, Maria Adelaide

AU - Lisotto, Carlo

AU - Martelletti, Paolo

AU - Moscato, Davide

AU - Panascia, Biagio

AU - Savi, Lidia

AU - Pini, Luigi Alberto

AU - Sances, Grazia

AU - Santoro, Patrizia

AU - Zanchin, Giorgio

AU - Omboni, Stefano

AU - Ferrari, Michel D.

AU - Fierro, Brigida

AU - Brighina, Filippo

PY - 2012/7

Y1 - 2012/7

N2 - The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4 h was 36 and 53 % for frovatriptan and 41 and 50 % for almotriptan (p = NS between treatments). Rate of pain free at 2 and 4 h was 19 and 47 % with frovatriptan and 29 and 54 % for almotriptan (p = NS).At 24 h, 62 %of frovatriptan-treated and 67 %of almotriptan-treated patients had pain relief, while 60 versus 67 % were pain free (p = NS). Recurrence at 24 h was significantly (p

AB - The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4 h was 36 and 53 % for frovatriptan and 41 and 50 % for almotriptan (p = NS between treatments). Rate of pain free at 2 and 4 h was 19 and 47 % with frovatriptan and 29 and 54 % for almotriptan (p = NS).At 24 h, 62 %of frovatriptan-treated and 67 %of almotriptan-treated patients had pain relief, while 60 versus 67 % were pain free (p = NS). Recurrence at 24 h was significantly (p

KW - Almotriptan

KW - Frovatriptan

KW - Menstrually related migraine

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=84865205953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865205953&partnerID=8YFLogxK

U2 - 10.1007/s10194-012-0455-4

DO - 10.1007/s10194-012-0455-4

M3 - Article

C2 - 22592864

AN - SCOPUS:84865205953

VL - 13

SP - 401

EP - 406

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 5

ER -